Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Association; 2013
   Google Scholar
• Shippee ND, Shah ND, Williams MD, et al. Differences in demographic composition and in work, social, and functional limitations among the populations with unipolar depression and bipolar disorder: results from a nationally representative sample. Health Qual Life Outcomes 2011;9:90
   PubMed Web of Science ®Google Scholar
• Pini S, de Queiroz V, Pagnin D, et al. Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol 2005;15:425–34
   PubMed Web of Science ®Google Scholar
• Shah N, Grover S, Rao Gp. Clinical practice guidelines for management of bipolar disorder. Indian J Psychiatry 2017;59:51
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry 2007;64:543
   PubMed Web of Science ®Google Scholar
• Esan O, Esan A. Epidemiology and burden of bipolar disorder in Africa: a systematic review of data from Africa. Soc Psychiatry Psychiatr Epidemiol 2016;51:93–100
   PubMed Web of Science ®Google Scholar
• The National Institute of Mental Health. Bipolar Disorder [Internet]. Bethesda, MD; 2017. Available at: https://www.nimh.nih.gov/health/statistics/bipolar-disorder.shtml [Last accessed January 26, 2017]
   Google Scholar
• Fagiolini A, Forgione R, Maccari M, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord 2013;148:161–9
   PubMed Web of Science ®Google Scholar
• Young AH, Rigney U, Shaw S, et al. Annual cost of managing bipolar disorder to the UK healthcare system. J Affect Disord 2011;133:450–6
   PubMed Web of Science ®Google Scholar
• Kleine-Budde K, Touil E, Moock J, et al. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord 2014;16:337–53
   PubMed Web of Science ®Google Scholar
• Cloutier M, Greene M, Guerin A, et al. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord 2017;226:45–51
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159:1–50
   Web of Science ®Google Scholar
• López-Muñoz F, Shen WW, D’Ocon P, et al. A history of the pharmacological treatment of bipolar disorder. Int J Mol Sci 2018;19:2143
   PubMed Web of Science ®Google Scholar
• Taylor DM, Cornelius V, Smith L, et al. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand 2014;130:452–69
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016;30:495–53
   PubMed Web of Science ®Google Scholar
• Malhi GS, Outhred T, Morris G, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary. Med J Aust 2018;208:219–25
   PubMed Web of Science ®Google Scholar
• Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord 2017;217:266–80
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care [Internet]. Manchester: National Institute for Health and Care Excellence; 2014. Available at: https://www.nice.org.uk/guidance/cg185 [Last accessed September 18, 2018]
   Google Scholar
• Rosa AR, Reinares M, Michalak EE, et al. Functional impairment and disability across mood states in bipolar disorder. Value Health 2010;13:984–8
   PubMed Web of Science ®Google Scholar
• Kora K, Saylan M, Akkaya C, et al. Predictive factors for time to remission and recurrence in patients treated for acute mania: health outcomes of manic episodes (HOME) study. Prim Care Companion J Clin Psychiatry 2008;10:114–19
   PubMedGoogle Scholar
• Berger A, Edelsberg J, Sanders KN, et al. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study. BMC Psychiatry 2012;12:99
   PubMed Web of Science ®Google Scholar
• Rascati KL, Richards KM, Ott CA, et al. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatr Serv 2011;62:1032–40
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Ng-Mak D, Solem CT, et al. Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis. Ther Adv Psychopharmacol 2016;6:355–68
   PubMed Web of Science ®Google Scholar
• Gianfrancesco FD, Sajatovic M, Rajagopalan K, et al. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin Ther 2008;30:1358–74
   PubMed Web of Science ®Google Scholar
• Jiang Y, Ni W. Estimating the impact of sdherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization. Pharmacotherapy 2015;35:813–22
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453–60
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176:109–13
   PubMed Web of Science ®Google Scholar
• Hong J, Reed C, Novick D, et al. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Res 2011;190:110–14
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70(Suppl 4):1–46; quiz 47–8
   PubMed Web of Science ®Google Scholar
• Hui Poon S, Sim K, Baldessarini RJ. Pharmacological approaches for treatment-resistant bipolar disorder. Curr Neuropharmacol 2015;13:592–604
   PubMed Web of Science ®Google Scholar
• Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229–33
   PubMed Web of Science ®Google Scholar
• Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177–86
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Glynn RJ, Avorn J, et al. Untangling the relationship between medication adherence and post–myocardial infarction outcomes. Am Heart J 2014;167:51–58.e5
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–19
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. HCUP chronic condition indicator [Internet]. Rockville, MD: Healthcare Cost and Utilization Project (HCUP); 2015. Available at: www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp [Last accessed November 30, 2017]
   Google Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action [Internet]. Geneva: World Health Organization; 2003. Available at: http://books.google.com/books?hl=en&lr=&id=kcYUTH8rPiwC&oi=fnd&pg=PR5&dq=%22VI+%E2%80%93+How+can+improved+adherence+be+translated+into%22+%22XIII+%E2%80%93%22+%22III+%E2%80%93+Disease-specific%22+%22VIII+%E2%80%93+Cancer+(palliative%22+%22XI+%E2%80%93%22+%22X+%E2%80%93%22+%22VII+%E2%80%93%22+%22XII+%E2%80%93%22+&ots = tz5Kir5cv_&sig = c5FxwOS1GP1PLX8P5yKo_CJzhyA [Last accessed March 5, 2013]
   Google Scholar
• MacDonald L, Chapman S, Syrett M, et al. Improving medication adherence in bipolar disorder: a systematic review and meta-analysis of 30 years of intervention trials. J Affect Disord 2016;194:202–21
   PubMed Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ 2018;21:127–34
   PubMed Web of Science ®Google Scholar
• Yan T, Greene M, Chang E, et al. Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar I disorder: a real-world study using US claims data. Adv Ther 2018;35:1612–1625
   Google Scholar
• Zhu B, Kulkarni PM, Stensland MD, et al. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder. Curr Med Res Opin 2007;23:2805–14
   Google Scholar
• Bergeson JG, Kalsekar I, Jing Y, et al. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics. Am Health Drug Benefits 2012;5:379–86
   PubMedGoogle Scholar
• Brown JD, Doshi PA, Talbert JC. Utilization of free medication samples in the United States in a nationally representative sample: 2009–2013. Res Social Adm Pharm 2017;13:193–200
   PubMed Web of Science ®Google Scholar
• Doshi JA, Li P, Desai S, et al. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia. J Med Econ 2017;20:1252–60
   PubMed Web of Science ®Google Scholar